CJC-1295 {No DAC} / Mod GRF {1-29} 5MG

CJC-1295 No DAC Overview

CJC-1295 (No DAC) 10 mg is a synthetic, long-acting GHRH analog designed to stimulate endogenous growth hormone (GH) secretion without the extended half-life conferred by the Drug Affinity Complex (DAC). The absence of DAC results in a shorter duration of action compared to CJC-1295 with DAC, but maintains the ability to increase pulsatile GH release and IGF-I production.^[1][2]

Mechanism of Action

CJC-1295 binds to GHRH receptors on pituitary somatotropes, promoting synthesis and release of GH, which in turn elevates IGF-I while preserving physiological GH pulsatility.^[2] GHRH analogs also act on extrapituitary tissues expressing GHRH receptors, including cardiac, pancreatic, and immune cells.^[3][4]

Clinical Effects & Applications

• Endocrine: Dose-dependent increases in mean plasma GH (2–10× baseline) and IGF-I (1.5–3×) in healthy adults after s.c. dosing, with effects lasting several days.^[1][2][5]
• Body Composition: Chronic GHRH analog use elevates IGF-I to youthful ranges, increases lean mass, and reduces adiposity in older adults and GH-deficient states.^[6]
• Regenerative Medicine: GHRH agonists support tissue repair, enhance post-infarct cardiac function, and improve pancreatic β-cell survival in preclinical models.^[3][4][7]
• Muscle Protection: GHS analogs (including CJC-1295) protect skeletal muscle mitochondria and aid recovery in cachexia and ischemia-reperfusion injury.^[7]
• Other Effects: Potential to accelerate wound healing, modulate immune responses, and provide neuroprotection (e.g., diabetic retinopathy, neurodegeneration) in models.^[3][4]

Safety & Tolerability

CJC-1295 has been well tolerated in clinical trials with no serious adverse events reported at doses up to 60 µg/kg.^[1] The shorter half-life of the No DAC form may reduce risk of sustained supraphysiologic GH/IGF-I exposure.

Summary

CJC-1295 No DAC is a potent GHRH analog that increases endogenous GH and IGF-I, with benefits reported for body composition, tissue regeneration, and muscle protection. Compared to DAC-containing forms, its shorter duration may offer advantages for titrating physiological GH exposure. Further studies are needed to define long-term safety, optimal dosing, and indications.^{[3][1][4][2][6][7][5]}

References

1. Teichman SL, Neale A, Lawrence B, et al. J Clin Endocrinol Metab. 2006;91(3):799-805. doi:10.1210/jc.2005-1536.
2. Ionescu M, Frohman LA. J Clin Endocrinol Metab. 2006;91(12):4792-7. doi:10.1210/jc.2006-1702.
3. Schally AV, Zhang X, Cai R, et al. Endocrinology. 2019;160(7):1600-1612. doi:10.1210/en.2019-00111.
4. Schally AV, Cai R, Zhang X, Sha W, Wangpaichitr M. Rev Endocr Metab Disord. 2025;26(3):385-396. doi:10.1007/s11154-024-09929-2.
5. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Growth Horm IGF Res. 2009;19(6):471-7. doi:10.1016/j.ghir.2009.03.001.
6. Merriam GR, Schwartz RS, Vitiello MV. Endocrine. 2003;22(1):41-8. doi:10.1385/ENDO:22:1:41.
7. Bresciani E, Rizzi L, Coco S, et al. Int J Mol Sci. 2019;20(18):E4361. doi:10.3390/ijms20184361.

All COA’s avail upon request by email info@truformlabs.com.

Storage & Handling (Research Use)

• Lyophilized (dry) peptide: Store sealed at −20 °C (long-term). Short-term storage up to 2–3 weeks at 2–8 °C is acceptable.
• After reconstitution: Store at 2–8 °C and use within 7 days, or aliquot into sterile vials and freeze at −20 °C for up to 3 months.
• Light & moisture: Protect from light; keep container tightly closed to avoid moisture uptake.
• Freeze–thaw: Avoid repeated freeze–thaw cycles (use aliquots).
• Solvent compatibility: Choose sterile solvent compatible with your protocol; filter-sterilize if required by your procedures.
• Labeling: Clearly label aliquots with concentration, solvent, and date of preparation.

Storage guidance is general for research peptides and may be adjusted per your lab SOP.